Context Therapeutics (CNTX) Institutional Ownership $0.91 -0.04 (-4.50%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.91 0.00 (-0.03%) As of 01/31/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Context Therapeutics (NASDAQ:CNTX)CurrentInstitutional OwnershipPercentage14.03%Number ofInstitutional Buyers(last 12 months)12TotalInstitutional Inflows(last 12 months)$43.67MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$1.28M Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CNTX Institutional Buying and Selling by Quarter Context Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails1/17/2025 Clear Harbor Asset Management LLC57,804$61K0.0%+60.6%0.077% 11/27/2024Franklin Resources Inc.1,853,988$3.69M0.0%N/A2.472% 11/16/2024Geode Capital Management LLC575,899$1.13M0.0%-6.8%0.768% 11/15/2024Y Intercept Hong Kong Ltd45,635$89K0.0%N/A0.061% 11/15/2024State Street Corp111,907$219K0.0%+21.5%0.149% 11/14/2024Ally Bridge Group NY LLC1,757,524$3.45M1.8%-6.8%2.343% 11/13/2024Great Point Partners LLC6,934,982$13.59M4.0%-6.5%9.247% 8/20/2024Nantahala Capital Management LLC1,935,484$3.88M0.2%N/A2.581% 8/16/2024Driehaus Capital Management LLC2,258,065$4.53M0.0%N/A3.011% 8/15/2024Blue Owl Capital Holdings LP5,161,290$10.35M2.9%N/A6.882% Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/2024Affinity Asset Advisors LLC1,619,140$3.25M0.4%+392.4%2.159% 8/14/2024Great Point Partners LLC7,419,355$14.88M2.8%N/A9.893% 8/14/2024Ally Bridge Group NY LLC1,886,232$3.78M2.3%+159.8%2.515% 8/9/2024Renaissance Technologies LLC65,200$131K0.0%+63.4%0.087% 5/29/2024Opaleye Management Inc.1,108,357$1.53M0.3%+13.7%1.478% 2/15/2024Opaleye Management Inc.975,000$1.10M0.3%N/A6.107% 11/15/2023Affinity Asset Advisors LLC328,817$497K0.1%+22.9%2.059% 8/21/2023Affinity Asset Advisors LLC267,574$428K0.1%N/A1.675% 7/21/2023 Clear Harbor Asset Management LLC36,000$58K0.0%N/A0.225% 2/16/2023AIGH Capital Management LLC1,143,745$745K0.2%-11.5%7.162% 2/14/2023swisspartners Ltd.180,000$119K0.2%+111.8%1.127% 11/14/2022Worth Venture Partners LLC322,628$358K0.2%+8.4%2.021% 11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532% 8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291% 8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535% 5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090% 2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501% 2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128% 2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955% 2/9/2022swisspartners Ltd.42,235$114K0.1%N/A0.385% (Data available from 1/1/2016 forward) CNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CNTX shares? During the previous two years, 15 institutional investors and hedge funds held shares of Context Therapeutics. The most heavily invested institutionals were Great Point Partners LLC ($13.59M), Blue Owl Capital Holdings LP ($10.35M), Driehaus Capital Management LLC ($4.53M), Nantahala Capital Management LLC ($3.88M), Franklin Resources Inc. ($3.69M), Ally Bridge Group NY LLC ($3.45M), and Affinity Asset Advisors LLC ($3.25M).Learn more on CNTX's institutional investors. What percentage of Context Therapeutics stock is owned by institutional investors? 14.03% of Context Therapeutics stock is owned by institutional investors. Learn more on CNTX's institutional investor holdings. Which institutional investors have been buying Context Therapeutics stock? Of the 13 institutional investors that purchased Context Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Great Point Partners LLC ($7.42M), Blue Owl Capital Holdings LP ($5.16M), Driehaus Capital Management LLC ($2.26M), Nantahala Capital Management LLC ($1.94M), Franklin Resources Inc. ($1.85M), Affinity Asset Advisors LLC ($1.62M), and Ally Bridge Group NY LLC ($1.16M). How much institutional buying is happening at Context Therapeutics? Institutional investors have bought a total of 22,759,499 shares in the last 24 months. This purchase volume represents approximately $44.31M in transactions. Which Context Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Context Therapeutics stock in the last 24 months: Great Point Partners LLC ($484.37K), AIGH Capital Management LLC ($148.03K), Ally Bridge Group NY LLC ($128.71K), and Geode Capital Management LLC ($42.28K). How much institutional selling is happening at Context Therapeutics? Institutional investors have sold a total of 803,382 shares in the last 24 months. This volume of shares sold represents approximately $1.38M in transactions. Related Companies ITOS Major Shareholders TRVI Major Shareholders DSGN Major Shareholders AVIR Major Shareholders AQST Major Shareholders RZLT Major Shareholders IMMP Major Shareholders CCCC Major Shareholders VYGR Major Shareholders YMAB Major Shareholders This page (NASDAQ:CNTX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
